NADSYN1
Glutamine-dependent NAD(+) synthetase
Also known as: FLJ10631, NADE_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6IA69
- Gene
- NADSYN1
- Ensembl
- ENSG00000172890
- Chromosome
- 11
- Canonical length
- 706 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Vesicles,Cytosol
- Quaternary structure
- Homohexamer
OverviewNCBI Gene
Nicotinamide adenine dinucleotide (NAD) is a coenzyme in metabolic redox reactions, a precursor for several cell signaling molecules, and a substrate for protein posttranslational modifications. NAD synthetase (EC 6.3.5.1) catalyzes the final step in the biosynthesis of NAD from nicotinic acid adenine dinucleotide (NaAD).[supplied by OMIM, Apr 2004]
Canonical amino-acid sequenceUniProt
706 residues, UniProt reviewed canonical sequence.
>Q6IA69|NADSYN1
1 MGRKVTVATC ALNQWALDFE GNLQRILKSI EIAKNRGARY RLGPELEICG YGCWDHYYES
61 DTLLHSFQVL AALVESPVTQ DIICDVGMPV MHRNVRYNCR VIFLNRKILL IRPKMALANE
121 GNYRELRWFT PWSRSRHTEE YFLPRMIQDL TKQETVPFGD AVLVTWDTCI GSEICEELWT
181 PHSPHIDMGL DGVEIITNAS GSHQVLRKAN TRVDLVTMVT SKNGGIYLLA NQKGCDGDRL
241 YYDGCAMIAM NGSVFAQGSQ FSLDDVEVLT ATLDLEDVRS YRAEISSRNL AASRASPYPR
301 VKVDFALSCH EDLLAPISEP IEWKYHSPEE EISLGPACWL WDFLRRSQQA GFLLPLSGGV
361 DSAATACLIY SMCCQVCEAV RSGNEEVLAD VRTIVNQISY TPQDPRDLCG RILTTCYMAS
421 KNSSQETCTR ARELAQQIGS HHISLNIDPA VKAVMGIFSL VTGKSPLFAA HGGSSRENLA
481 LQNVQARIRM VLAYLFAQLS LWSRGVHGGL LVLGSANVDE SLLGYLTKYD CSSADINPIG
541 GISKTDLRAF VQFCIQRFQL PALQSILLAP ATAELEPLAD GQVSQTDEED MGMTYAELSV
601 YGKLRKVAKM GPYSMFCKLL GMWRHICTPR QVADKVKRFF SKYSMNRHKM TTLTPAYHAE
661 NYSPEDNRFD LRPFLYNTSW PWQFRCIENQ VLQLERAEPQ SLDGVDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NADSYN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 64 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 64 nTPM
- spleen: 57 nTPM
- esophagus: 55 nTPM
- small intestine: 49 nTPM
- liver: 49 nTPM
- colon: 47 nTPM
Single-cell type
- neutrophil progenitors: 102 nCPM
- late spermatids: 94 nCPM
- enterocytes: 82 nCPM
- esophageal apical cells: 80 nCPM
- esophageal suprabasal cells: 79 nCPM
- colonocytes: 69 nCPM
Immune cell
- myeloid DC: 31 nTPM
- classical monocyte: 28 nTPM
- intermediate monocyte: 25 nTPM
- plasmacytoid DC: 23 nTPM
- non-classical monocyte: 23 nTPM
- total PBMC: 21 nTPM
Brain region
- white matter: 28 nTPM
- medulla oblongata: 25 nTPM
- thalamus: 23 nTPM
- pons: 22 nTPM
- cerebral cortex: 22 nTPM
- choroid plexus: 20 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NADSYN1.
Disease | AllUniProt
Conditions NADSYN1 is implicated in, by any mechanism.
- Vertebral, cardiac, renal, and limb defects syndrome 3 (VCRL3) MIM:618845
Disease | GeneticClinVar
15 pathogenic / likely-pathogenic of 177 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Vertebral, cardiac, renal, and limb defects syndrome 3
- Congenital NAD deficiency disorder
- NADSYN1-related disorder
- Neurodevelopmental delay
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.94
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.71
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 'de novo' NAD+ biosynthetic process from L-tryptophan
- NAD+ biosynthetic process
- NAD+ biosynthetic process via the salvage pathway
Molecular functions
- ATP binding
- glutaminase activity
- NAD+ synthase (glutamine-hydrolyzing) activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Carbon-nitrogen hydrolase
- Rossmann-like alpha/beta/alpha sandwich fold
- NAD/GMP synthase
- Carbon-nitrogen hydrolase superfamily
- Carbon-nitrogen hydrolase
- NAD synthase
- NAD(+) synthetase
- Glutamine-dependent NAD(+) synthetase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NADSYN1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NADSYN1 as an antibody target. Whether an autoantibody or antibody against NADSYN1 could matter depends on whether native NADSYN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NADSYN1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NADSYN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...